Wenhua Liang1,2, Hengrui Liang1,2, Limin Ou1, Binfeng Chen3, Ailan Chen1,4, Caichen Li1, Yimin Li1,5, Weijie Guan1, Ling Sang1,5,6, Jiatao Lu4, Yuanda Xu1,5,7, Guoqiang Chen8, Haiyan Guo9, Jun Guo10, Zisheng Chen1,11, Yi Zhao1,2, Shiyue Li1, Nuofu Zhang1,4, Nanshan Zhong1, Jianxing He1,2. 1. National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. 2. Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. 3. Department of Rheumatology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. 4. Hankou Hospital, Wuhan, China. 5. Department of Intensive Care Unit, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. 6. Jinyintan Hospital, Wuhan, China. 7. Tongji Medical College, Union Hospital, Huazhong University of Science and Technology, Wuhan, Hubei, China. 8. The First People Hospital of Foshan, Foshan, China. 9. Nanhai Hospital, Foshan, China. 10. Daye Hospital, Hubei, China. 11. The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan, China.
Abstract
Importance: Early identification of patients with novel coronavirus disease 2019 (COVID-19) who may develop critical illness is of great importance and may aid in delivering proper treatment and optimizing use of resources. Objective: To develop and validate a clinical score at hospital admission for predicting which patients with COVID-19 will develop critical illness based on a nationwide cohort in China. Design, Setting, and Participants: Collaborating with the National Health Commission of China, we established a retrospective cohort of patients with COVID-19 from 575 hospitals in 31 provincial administrative regions as of January 31, 2020. Epidemiological, clinical, laboratory, and imaging variables ascertained at hospital admission were screened using Least Absolute Shrinkage and Selection Operator (LASSO) and logistic regression to construct a predictive risk score (COVID-GRAM). The score provides an estimate of the risk that a hospitalized patient with COVID-19 will develop critical illness. Accuracy of the score was measured by the area under the receiver operating characteristic curve (AUC). Data from 4 additional cohorts in China hospitalized with COVID-19 were used to validate the score. Data were analyzed between February 20, 2020 and March 17, 2020. Main Outcomes and Measures: Among patients with COVID-19 admitted to the hospital, critical illness was defined as the composite measure of admission to the intensive care unit, invasive ventilation, or death. Results: The development cohort included 1590 patients. the mean (SD) age of patients in the cohort was 48.9 (15.7) years; 904 (57.3%) were men. The validation cohort included 710 patients with a mean (SD) age of 48.2 (15.2) years, and 382 (53.8%) were men and 172 (24.2%). From 72 potential predictors, 10 variables were independent predictive factors and were included in the risk score: chest radiographic abnormality (OR, 3.39; 95% CI, 2.14-5.38), age (OR, 1.03; 95% CI, 1.01-1.05), hemoptysis (OR, 4.53; 95% CI, 1.36-15.15), dyspnea (OR, 1.88; 95% CI, 1.18-3.01), unconsciousness (OR, 4.71; 95% CI, 1.39-15.98), number of comorbidities (OR, 1.60; 95% CI, 1.27-2.00), cancer history (OR, 4.07; 95% CI, 1.23-13.43), neutrophil-to-lymphocyte ratio (OR, 1.06; 95% CI, 1.02-1.10), lactate dehydrogenase (OR, 1.002; 95% CI, 1.001-1.004) and direct bilirubin (OR, 1.15; 95% CI, 1.06-1.24). The mean AUC in the development cohort was 0.88 (95% CI, 0.85-0.91) and the AUC in the validation cohort was 0.88 (95% CI, 0.84-0.93). The score has been translated into an online risk calculator that is freely available to the public (http://118.126.104.170/). Conclusions and Relevance: In this study, a risk score based on characteristics of COVID-19 patients at the time of admission to the hospital was developed that may help predict a patient's risk of developing critical illness.
Importance: Early identification of patients with novel coronavirus disease 2019 (COVID-19) who may develop critical illness is of great importance and may aid in delivering proper treatment and optimizing use of resources. Objective: To develop and validate a clinical score at hospital admission for predicting which patients with COVID-19 will develop critical illness based on a nationwide cohort in China. Design, Setting, and Participants: Collaborating with the National Health Commission of China, we established a retrospective cohort of patients with COVID-19 from 575 hospitals in 31 provincial administrative regions as of January 31, 2020. Epidemiological, clinical, laboratory, and imaging variables ascertained at hospital admission were screened using Least Absolute Shrinkage and Selection Operator (LASSO) and logistic regression to construct a predictive risk score (COVID-GRAM). The score provides an estimate of the risk that a hospitalized patient with COVID-19 will develop critical illness. Accuracy of the score was measured by the area under the receiver operating characteristic curve (AUC). Data from 4 additional cohorts in China hospitalized with COVID-19 were used to validate the score. Data were analyzed between February 20, 2020 and March 17, 2020. Main Outcomes and Measures: Among patients with COVID-19 admitted to the hospital, critical illness was defined as the composite measure of admission to the intensive care unit, invasive ventilation, or death. Results: The development cohort included 1590 patients. the mean (SD) age of patients in the cohort was 48.9 (15.7) years; 904 (57.3%) were men. The validation cohort included 710 patients with a mean (SD) age of 48.2 (15.2) years, and 382 (53.8%) were men and 172 (24.2%). From 72 potential predictors, 10 variables were independent predictive factors and were included in the risk score: chest radiographic abnormality (OR, 3.39; 95% CI, 2.14-5.38), age (OR, 1.03; 95% CI, 1.01-1.05), hemoptysis (OR, 4.53; 95% CI, 1.36-15.15), dyspnea (OR, 1.88; 95% CI, 1.18-3.01), unconsciousness (OR, 4.71; 95% CI, 1.39-15.98), number of comorbidities (OR, 1.60; 95% CI, 1.27-2.00), cancer history (OR, 4.07; 95% CI, 1.23-13.43), neutrophil-to-lymphocyte ratio (OR, 1.06; 95% CI, 1.02-1.10), lactate dehydrogenase (OR, 1.002; 95% CI, 1.001-1.004) and direct bilirubin (OR, 1.15; 95% CI, 1.06-1.24). The mean AUC in the development cohort was 0.88 (95% CI, 0.85-0.91) and the AUC in the validation cohort was 0.88 (95% CI, 0.84-0.93). The score has been translated into an online risk calculator that is freely available to the public (http://118.126.104.170/). Conclusions and Relevance: In this study, a risk score based on characteristics of COVID-19patients at the time of admission to the hospital was developed that may help predict a patient's risk of developing critical illness.
Authors: A M Neill; I R Martin; R Weir; R Anderson; A Chereshsky; M J Epton; R Jackson; M Schousboe; C Frampton; S Hutton; S T Chambers; G I Town Journal: Thorax Date: 1996-10 Impact factor: 9.139
Authors: Joshua P Metlay; Grant W Waterer; Ann C Long; Antonio Anzueto; Jan Brozek; Kristina Crothers; Laura A Cooley; Nathan C Dean; Michael J Fine; Scott A Flanders; Marie R Griffin; Mark L Metersky; Daniel M Musher; Marcos I Restrepo; Cynthia G Whitney Journal: Am J Respir Crit Care Med Date: 2019-10-01 Impact factor: 21.405
Authors: Mark H Ebell; Xinyan Cai; Robert Lennon; Derjung M Tarn; Arch G Mainous; Aleksandra E Zgierska; Bruce Barrett; Wen-Jan Tuan; Kevin Maloy; Munish Goyal; Alex Krist Journal: J Am Board Fam Med Date: 2021-02 Impact factor: 2.657
Authors: Christopher J Colombo; Rhonda E Colombo; Ryan C Maves; Angela R Branche; Stuart H Cohen; Marie-Carmelle Elie; Sarah L George; Hannah J Jang; Andre C Kalil; David A Lindholm; Richard A Mularski; Justin R Ortiz; Victor Tapson; C Jason Liang Journal: Crit Care Explor Date: 2021-07-13
Authors: Peter D Sottile; David Albers; Peter E DeWitt; Seth Russell; J N Stroh; David P Kao; Bonnie Adrian; Matthew E Levine; Ryan Mooney; Lenny Larchick; Jean S Kutner; Matthew K Wynia; Jeffrey J Glasheen; Tellen D Bennett Journal: J Am Med Inform Assoc Date: 2021-10-12 Impact factor: 4.497
Authors: Joseph Balnis; Andy Madrid; Kirk J Hogan; Lisa A Drake; Hau C Chieng; Anupama Tiwari; Catherine E Vincent; Amit Chopra; Peter A Vincent; Michael D Robek; Harold A Singer; Reid S Alisch; Ariel Jaitovich Journal: Clin Epigenetics Date: 2021-05-25 Impact factor: 6.551
Authors: David M Nemer; Bryan R Wilner; Alicia Burkle; Jose Aguilera; Joseph Adewumi; Carl Gillombardo; Oussama Wazni; Venu Menon; Shannon Pengel; Meredith Foxx; Marc Petre; Aaron C Hamilton; Daniel J Cantillon Journal: J Hosp Med Date: 2021-01 Impact factor: 2.960
Authors: Austin S Kilaru; Kathleen Lee; Lindsay Grossman; Zachary Mankoff; Christopher K Snider; Eric Bressman; Stefanie B Porges; Keith C Hemmert; Scott R Greysen; David A Asch; Mucio K Delgado Journal: J Clin Med Date: 2021-05-03 Impact factor: 4.241